MAGEA4 and synovial sarcoma: A phase I clinical trial using the MAGE-A4-specific TCR-T cell product afamitresgene autoleucel for solid tumor treatment achieved a 44% response rate in synovial sarcoma patients, demonstrating MAGE-A4’s potential in cancer immunotherapy (Hong et al. 2023).